# A Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Single Dose Tablet Under Fed Conditions in Healthy Participants

> **NCT02889367** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 60 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Odalasvir 100 mg
- **DRUG:** Placebo
- **DRUG:** Odalasvir 500 mg
- **DRUG:** Odalasvir (Up to maximum 1000 mg)

## Key facts

- **NCT ID:** NCT02889367
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-12
- **Primary completion:** 2017-03-04
- **Final completion:** 2017-03-04
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2017-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02889367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02889367, "A Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Single Dose Tablet Under Fed Conditions in Healthy Participants". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02889367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*